{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T02:19:10Z","timestamp":1773368350005,"version":"3.50.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,12]]},"DOI":"10.7759\/cureus.105104","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T14:35:37Z","timestamp":1773326137000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinical and Genetic Characterization of a Patient With SEC63-Related Autosomal Dominant Polycystic Liver Disease and an IFT140 Pathogenic Variant Associated With Polycystic Kidney Disease"],"prefix":"10.7759","author":[{"given":"Alan G","family":"Ortega-Mac\u00edas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Udita","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomas","family":"Escobar Gil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jawairia","family":"Memon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo R","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2021.11.016","article-title":"Monoallelic IFT140 pathogenic variants are an important cause of the autosomal dominant polycystic kidney-spectrum phenotype","volume":"109","author":"Senum SR","year":"2022","unstructured":"Senum SR, Li YS, Benson KA, et al.. Monoallelic IFT140 pathogenic variants are an important cause of the autosomal dominant polycystic kidney-spectrum phenotype. Am J Hum Genet. 2022, 109:136-156. 10.1016\/j.ajhg.2021.11.016","journal-title":"Am J Hum Genet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0004.2009.01353.x","article-title":"Secondary and tertiary structure modeling reveals effects of novel mutations in polycystic liver disease genes PRKCSH and SEC63","volume":"78","author":"Waanders E","year":"2010","unstructured":"Waanders E, Venselaar H, te Morsche RH, et al.. Secondary and tertiary structure modeling reveals effects of novel mutations in polycystic liver disease genes PRKCSH and SEC63. Clin Genet. 2010, 78:47-56. 10.1111\/j.1399-0004.2009.01353.x","journal-title":"Clin Genet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1172\/JCI90129","article-title":"Isolated polycystic liver disease genes define effectors of polycystin-1 function","volume":"127","author":"Besse W","year":"2017","unstructured":"Besse W, Dong K, Choi J, et al.. Isolated polycystic liver disease genes define effectors of polycystin-1 function. J Clin Invest. 2017, 127:1772-1785. 10.1172\/JCI90129","journal-title":"J Clin Invest"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/humu.9441","article-title":"Extensive mutational analysis of PRKCSH and SEC63 broadens the spectrum of polycystic liver disease","volume":"27","author":"Waanders E","year":"2006","unstructured":"Waanders E, te Morsche RH, de Man RA, Jansen JB, Drenth JP. Extensive mutational analysis of PRKCSH and SEC63 broadens the spectrum of polycystic liver disease. Hum Mutat. 2006, 27:830. 10.1002\/humu.9441","journal-title":"Hum Mutat"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v12.i3.72","article-title":"Polycystic liver disease: classification, diagnosis, treatment process, and clinical management","volume":"12","author":"Zhang ZY","year":"2020","unstructured":"Zhang ZY, Wang ZM, Huang Y. Polycystic liver disease: classification, diagnosis, treatment process, and clinical management. World J Hepatol. 2020, 12:72-83. 10.4254\/wjh.v12.i3.72","journal-title":"World J Hepatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/ng1357","article-title":"Mutations in SEC63 cause autosomal dominant polycystic liver disease","volume":"36","author":"Davila S","year":"2004","unstructured":"Davila S, Furu L, Gharavi AG, et al.. Mutations in SEC63 cause autosomal dominant polycystic liver disease. Nat Genet. 2004, 36:575-577. 10.1038\/ng1357","journal-title":"Nat Genet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae026","article-title":"Monoallelic pathogenic IFT140 variants are a common cause of autosomal dominant polycystic kidney disease-spectrum phenotype","volume":"17","author":"Dordoni C","year":"2024","unstructured":"Dordoni C, Zeni L, Toso D, et al.. Monoallelic pathogenic IFT140 variants are a common cause of autosomal dominant polycystic kidney disease-spectrum phenotype. Clin Kidney J. 2024, 17:sfae026. 10.1093\/ckj\/sfae026","journal-title":"Clin Kidney J"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2023.100668","article-title":"Genetic counseling in kidney disease: a perspective","volume":"5","author":"Stein Q","year":"2023","unstructured":"Stein Q, Westemeyer M, Darwish T, et al.. Genetic counseling in kidney disease: a perspective. Kidney Med. 2023, 5:100668. 10.1016\/j.xkme.2023.100668","journal-title":"Kidney Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.11.024","article-title":"Clinical management of polycystic liver disease","volume":"68","author":"van Aerts RM","year":"2018","unstructured":"van Aerts RM, van de Laarschot LF, Banales JM, Drenth JP. Clinical management of polycystic liver disease. J Hepatol. 2018, 68:827-837. 10.1016\/j.jhep.2017.11.024","journal-title":"J Hepatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-022-00617-7","article-title":"Genetics, pathobiology and therapeutic opportunities of polycystic liver disease","volume":"19","author":"Olaizola P","year":"2022","unstructured":"Olaizola P, Rodrigues PM, Caballero-Camino FJ, et al.. Genetics, pathobiology and therapeutic opportunities of polycystic liver disease. Nat Rev Gastroenterol Hepatol. 2022, 19:585-604. 10.1038\/s41575-022-00617-7","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2015.59","article-title":"Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"88","author":"Chapman AB","year":"2015","unstructured":"Chapman AB, Devuyst O, Eckardt KU, et al.. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2015, 88:17-27. 10.1038\/ki.2015.59","journal-title":"Kidney Int"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.16.16130","article-title":"Efficacy and safety of aspiration sclerotherapy of simple hepatic cysts: a systematic review","volume":"208","author":"Wijnands TF","year":"2017","unstructured":"Wijnands TF, G\u00f6rtjes AP, Gevers TJ, et al.. Efficacy and safety of aspiration sclerotherapy of simple hepatic cysts: a systematic review. AJR Am J Roentgenol. 2017, 208:201-207. 10.2214\/AJR.16.16130","journal-title":"AJR Am J Roentgenol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.15586\/codon.pkd.2015.ch4","article-title":"Diagnosis and treatment modalities of symptomatic polycystic kidney disease","author":"Guler S","year":"2015","unstructured":"Guler S, Cimen S, Hurton S, Molinari M. Diagnosis and treatment modalities of symptomatic polycystic kidney disease. Polycystic Kidney Disease. Codon Publications, Brisbane, Australia; 2015. 10.15586\/codon.pkd.2015.ch4"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2013101138","article-title":"Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials","volume":"26","author":"Irazabal MV","year":"2015","unstructured":"Irazabal MV, Rangel LJ, Bergstralh EJ, et al.. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol. 2015, 26:160-172. 10.1681\/ASN.2013101138","journal-title":"J Am Soc Nephrol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/470717-clinical-and-genetic-characterization-of-a-patient-with-sec63-related-autosomal-dominant-polycystic-liver-disease-and-an-ift140-pathogenic-variant-associated-with-polycystic-kidney-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T14:35:38Z","timestamp":1773326138000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/470717-clinical-and-genetic-characterization-of-a-patient-with-sec63-related-autosomal-dominant-polycystic-liver-disease-and-an-ift140-pathogenic-variant-associated-with-polycystic-kidney-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.105104","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,12]]}}}